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Myeloproliferative neoplasms such as essential thrombocythemia (ET) have been associated with glomerular disease on rare
instances. A case of ET associated with immunoglobulin A nephropathy (IgAN) is described in a 57-year-old man with a history
of hypertension. Progressively worsening renal function was noted in the patient along with unexplained mild thrombocytosis.
Pathological review of renal biopsy identified IgAN concurrently with newly diagnosed JAK2-mutated ET. The patient was
started on aspirin therapy and closely monitored for his renal function. A literature review of the association of ET and renal
disease revealed nine cases of ET associated with IgAN, focal segmental glomerulosclerosis, and fibrillary glomerulonephritis.
Comparison of the pathological features of the renal biopsies within the cases noted mesangial proliferation as a common
finding, which has been described to be potentiated by platelet-derived growth factor (PDGF). This commonality may represent
a link between ET and glomerular disease which deserves further attention in future cases. Improved management of such cases
depends on the recognition of the combined occurrence of ET and glomerular diseases and uncovering the shared pathogenesis
between platelets and glomeruli.
1. Introduction
Essential thrombocythemia (ET) is a type of myeloprolifera-
tive neoplasm (MPN) that results in an increased number of
platelets in circulation. The current 2016 WHO classification
for diagnosis of ET requires major criteria of a platelet count
equal to or over 450 × 103/L, demonstration of JAK2, MPL,
or CALR mutation, bone marrow biopsy with mature mega-
karyocyte proliferation but without significant production of
neutrophils, erythrocytes, or reticulin fibers, and lack of
meeting criteria for other myeloproliferative diseases. ET
can alternatively be diagnosed by meeting three of the major
criteria in addition to lone minor criteria of a clonal marker
or absence of evidence for reactive thrombocytosis [1, 2].
The presence of distinct genotypes is central to both the
diagnosis and, at times, treatment of MPNs. Where some
MPNs are the result of an individually distinct mutation,
others may stem from various genetic aberrations. For
instance, polycythemia vera (PV), a form of MPN that leads
to an increased concentration of hemoglobin and hematocrit,
is associated with a JAK2V615F mutation that has been seen
in approximately 95% of cases. In contrast, JAK2 mutations
are typically seen in 50-60% of ET cases [3]. In ET cases that
lack JAK2mutation, CALR andMPL genes have been shown
to possess mutation. Past cohorts studying ET patients found
that these mutations (JAK2, CALR, and MPL) are seen in
62-64%, 22-24%, and 4%, respectively [4, 5].
While patients with ET are at a known increased risk for
thrombotic conditions such as cerebral vascular accidents,
myocardial infarction, pulmonary embolism, and pregnancy
complications, there is a lesser known association between
ET and glomerulonephropathy. Various forms of glomerulo-
nephropathy have been reported in patientswithET including
IgA nephropathy (IgAN), focal segmental glomerulosclerosis
(FSGS), diffuse mesangial sclerosis, and fibrillary glomerulo-
nephritis [6–8]. Described here is a case of a 57-year-old
man diagnosed with ET that was subsequently diagnosed
with IgAN.
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2. Case Description
A 57-year-old Caucasian man with a history of chronic kid-
ney disease (CKD), essential hypertension, migraines, and
obstructive sleep apnea presented to the clinic for establish-
ment as a new patient. Besides occasional migraines, he did
not have any other immediate complaints. His blood pres-
sure was mildly elevated at 148/92mmHg while on lisinopril
10mg and propranolol 160mg daily, and physical examina-
tion was benign, including lack of lymphadenopathy, rashes,
or edema. Review of his laboratory results was notable for
worsened renal function in the past year from a serum creat-
inine (SCr) of 1.10mg/dL and globular filtration rate (GFR)
of 69.25mL/min to a SCr of 1.66mg/dL and GFR of
42.91mL/min. Initially, this was attributed to his angiotensin-
converting enzyme inhibitor (ACE-I); however, its discontinu-
ation did not result in recovery of renal function. Additional
review of records dating 6 years ago revealed thrombocytosis
of around 600 × 103/μL which was more recently in the
418‐440 × 103/μL range. The patient had never experienced
arterial or venous thrombotic events, and etiology of his
thrombocytosis had not been investigated in the past. Sev-
eral laboratory studies were ordered with focus on his CKD
and thrombocytosis.
Thrombocytosis was pursued with genetic mutation test-
ing, which returned with positive JAK2 mutation and nega-
tive BCR-ABL1. The patient was diagnosed with ET and
was started on aspirin. Hydroxyurea therapy was not indi-
cated given a platelet count of 419 × 103/μL.
Two months later, investigation of his progressive chronic
kidney disease had revealed proteinuria with 560mg/24 hours
urine protein content, and he was seen by a nephrologist.
The electrolytes, uric acid, glucose, serum lipid profile, hep-
atitis panel, liver function tests, prostate serum antigen, and
serum complement levels of C3 and C4 were normal. Serum
and urine protein electrophoresis did not identify significant
paraproteins. Further testing for autoimmune and systemic
disease was negative, which included sedimentation rate,
C-reactive protein, antinuclear antibody, and antiproteinase
3. Ultrasonography revealed normal renal parenchymal
echogenicity of both kidneys, which measured 10.9 cm in
length on the right and 9.9 cm on the left. There was mini-
mal postvoid bladder residual volume of 21mL, and no
hydronephrosis or solid renal mass was seen.
The patient agreed to undergo a renal biopsy. The speci-
mens were prepared in periodic acid-Schiff, trichrome and
silver stains. Microscopic analysis resulted in a diagnosis of
IgA predominant nephropathy (Figure 1).
In the following months, the patient was monitored rou-
tinely for findings such as hematuria, increased proteinuria,
and swelling. He was continued on lisinopril for mild pro-
teinuria. Repeat testing 3 months after his prior results found
an elevated SCr of 1.91mg/dL and GFR of 36.50mL/min.
Urine testing at that time however found improved protein-
uria with 23mg/24 urine. On subsequent follow-up visits,
the patient’s blood pressure remained in the range of 118-
140/82-92mmHg. His platelet count in the 6 months after
his renal biopsy remained consistently between 797 and
876 × 103/μL without cytoreductive therapy. Subsequently,
given that his SCr remained 1.6-1.7mg/dL with proteinuria
less than 300mg per day, it was decided to continue the
ACE-I without immunosuppressive therapy unless further
progression became evident.
3. Discussion
The development of glomerulonephropathy in patients with
MPNs is not well understood and is infrequently encoun-
tered. While cases have been described within many of the
myeloproliferative neoplasm subtypes, this association seems
to be more commonly documented within PV and primary
myelofibrosis (PMF). Cases of PV describing the develop-
ment of nephrotic range proteinuria often report FSGS fol-
lowing renal biopsy [7–9]. While FSGS is described in most
PV cases, some cases of PV-related nephropathies have also
described IgA nephropathy [10]. Furthermore, there is a
reported case for which Said et al. proposed the term
“MPN-related glomerulonephropathy” to distinguish MPN-
related glomerular disease from other common glomerular
diseases based on histopathologic findings. MPN-related glo-
merulonephropathy was characterized by (1) mesangial scle-
rosis and more pronounced mesangial proliferation, (2) a
lack of nodular mesangial sclerosis, (3) absence of immune
deposits, (4) presence of intracapillary hematopoietic cell(s),
and (5) segmental duplication of the glomerular basement
membrane with findings that mimic chronic thrombotic
microangiopathy (TMA) but without intracapillary fibrin
thrombi, arteriolar thrombotic lesions, or features of micro-
angiopathic hemolytic anemia [11].
Similar to PV, cases that describe ET-related glomerulo-
nephropathy often report findings of FSGS (Table 1). Nine
other cases were identified of glomerulonephropathy in
patients with ET and seemingly no other etiologic explana-
tion in a PubMed database search of the English literature
[12–15]. Our case presented above marks the tenth ET-
related nephropathy case and the second describing IgAN
in a patient with ET.
On comparison of the ET and glomerulonephropathy
previously described cases with ours, only the ET case in
Said et al. had the histological appearance of the proposed
MPN-related glomerulonephropathy. Four of the ten were
consistent with FSGS, two were not given an official diag-
nosis, two IgAN (including our case), one fibrillary glomer-
ulonephritis, and one MPN-related glomerulonephropathy.
Mesangial proliferation was a common finding as it is stated
in 9 out of 10 of the cases. Another is immune complex depo-
sition, being stated in 6 out of the 10. Our case shared the
mesangial proliferation and deposition of immune com-
plexes, which may be an affected process with the shared
pathophysiology of ET.
A possible pathogenic correlation between ET and glo-
merular disease could be with platelet-derived growth fac-
tor (PDGF) and its role in fibrotic processes such as
glomerulosclerosis and myelofibrosis. In a study of fibro-
genic growth factors in IgAN and FSGS, Stein-Oakley
et al. concluded that these glomeruli express higher levels
of PDGF receptors which were strongly associated with dis-
ease severity, particularly with FSGS. Likewise, the amount
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of mesangial proliferation was associated with the higher
expression of PDGF in glomeruli of patients with IgAN
and FSGS [16]. In studies comparing ET and PDGF levels,
mutations of JAK2, CALR, and MPL have been linked to
increased concentrations of PDGF, with CALR mutations
leading to three times higher levels than with the other
mutations. This has been used to offer an explanation as
to the significantly higher incidence of primary myelofibro-
sis in patients of ET and CALR mutation [17].
Increased fibrogenicity as a result of ET mutations also
stems from transforming growth factor-β (TGF-β). TGF-β
has also been proposed to have a role in glomerular diseases
in a process of podocyte injury that is described in the
early stages of FSGS. In the FSGS and ET case described by
Haraguchi et al., higher levels of TGF-β as well as PDGF were
found [14].
Similarly, PV-associated nephropathies have been
thought to involve fibrogenic cytokines such as PDGF. Addi-
tionally, it has been proposed that with the resultant hyper-
viscosity of PV, chronic increases in blood volume and
viscosity can lead to vascular damage to the intima of vessels,
with subsequent microthrombi causing renal capillary occlu-
sion that ultimately decrease glomerular filtration. This is




Figure 1: Renal biopsy pathology. Up to fourteen glomeruli were identified under light microscopy, and analysis found glomeruli with diffuse
thickening of capillary membranes (a, b). There was mild mesangial matrix expansion and hypercellularity (c, d). There was no evidence of
glomerular sclerosis. Segmental duplication of capillary walls with accumulation of eosinophilic deposits was noted between the duplicated
membranes. Silver stain reveals thickened capillary walls, duplication of basement membranes with eosinophilic deposits in between (e, f).
Trichrome stain showed mild to moderate focal interstitial fibrosis associated with tubular atrophy and drop out with scattered
lymphocytes within the fibrotic interstitium. No acute tubulitis was seen. Electron microscopy found diffuse effacement of podocyte foot
processes and prominent thickening of capillary loops by a combination of subendothelial deposits, basement membrane duplication, and
mesangial cell interposition. On immunofluorescence, there was a diffuse 2 to 3+ mesangial reaction and segmental capillary loop reaction
for IgA, IgM, C3, kappa, and lambda (g). The reaction for IgG was only 1+, and there was no reaction for C1q or fibrin. Pronase-retrieval
IgG stain on paraffin-embedded tissue was negative. The results indicated a diagnosis of IgA predominant nephropathy.
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hyperuricemia in patients with PV-related glomerulonephro-
pathy (8 of 23 described cases being IgA nephropathy) [10].
In the present case, cytoreductive therapy was not found
to be necessary given the lower risk and stable levels of
thrombocytosis. Interestingly, the use of anagrelide in ET
has been found to decrease the levels of PDGF which may
carry an important implication in the treatment of glomeru-
lonephropathies in patients with ET [18]. In consideration of
the importance of PDGF in the shared pathogenesis of these
conditions, other cytoreductive therapies such as interferon
and hydroxyurea would benefit from a study of their effects
on plasma PDGF levels. Even so, potential renal impairment
directly from these agents should be considered if treatment
is initiated. MPN patients who are on cytoreductive therapies
with profound renal impairment, which does not recover
with dosage decrease, may benefit from renal biopsies to
identify a concurrent glomerulonephropathy.
In the case described above, JAK2 mutation was present
and the glomerular injury had shownmesangial proliferation.
Glomerular sclerosis was not present, which may depend on
the specific mutation of ET and the subsequently induced
level of fibrogenesis. The other cases did not all specify which
ET gene mutation was found. This could be an area of
improvement as the role of ET and fibrogenesis in glomeru-
lonephropathy is further investigated.
4. Conclusion
As it stands, the rare combination in the present case of ET
and IgAN will likely proceed with separate management of
the renal disease and the ET. Until a clear understanding of
the combined pathogenesis is established, platelet numbers
will dictate only the treatment of ET and not worsening of
the renal function. Practice-changing management strategies
Table 1: Biopsy results of essential thrombocythemia and glomerulonephropathy cases.





Mesangial PAS (+) fibrillary deposits without
mesangial proliferation or crescent formation
(+) IgG on immunohistochemical staining
Weakly (+) IgA, IgM, and C3




Diffuse mesangial sclerosis with proliferation
Segmental capillary thickening immunohistochemical
staining (-)
FSGS Unknown Au et al. [7]
3 Female 39
Global & segmental sclerosis
Segmental mesangial IgM and C3 deposits
FSGS Unknown Au et al. [7]
4 Female 70
Mesangial proliferation
Foot process effacement on electron microscopy








Features of chronic thrombotic microangiopathy








IgM (+) on immunohistochemical staining
Weakly IgA (+) on immunohistochemical staining





Mesangial proliferation with crescent formation
IgG and IgA (+) on immunohistochemical staining
Dense deposits in the mesangium on electron
microscopy




Segmental sclerosis and hyalinosis
Segmental IgM (+) deposits















Membrane thickening with mesangial proliferation
IgG and IgA (+) on immunohistochemical staining
Foot podocyte effacement and subendothelial on
electron microscopy
IgA nephropathy 2 months
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can be obtained if clinicians can recognize the concurrence of
ET and glomerulonephropathy, and future studies are devel-
oped to better clarify associations of ET mutations and renal
histopathological findings.
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